In vivo experiments confirmed that kirenol at 30 mg/kg/d could effectively reduce the tumor volume and incidence of MNNG-stimulated gastric cancer in rats, reduce the levels of oxidative stress and inflammatory response through the NF-κB signaling cascade, and inhibit the expression of LDH in gastric cancer tissues, without reducing mice body weight. This evidence concerns the gene NFKB1 and gastric cancer.